NEULASTA SUMMARY
Neulasta™ (pegfilgrastim) is a covalent conjugate of recombinant methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene glycol.
Neulasta™ is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Neulasta (Pegfilgrastim)
Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? [2011.10.31]
Ziakas PD, Kourbeti IS.Both drugs are at least equally effective, though methodology and disease stratification in published trials warrant further improvement.
Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. [2010.07]
BACKGROUND: American Society of Clinical Oncology guidelines recommend the use of growth factor after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support. This randomized trial aims to demonstrate the noninferiority of pegfilgrastim (PEG) compared with filgrastim (FIL) after HDC... CONCLUSION: PEG is not inferior to FIL in hematological reconstitution and represents an effective alternative after HDC and PBSC.
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. [2010.06]
BACKGROUND: Filgrastim decreases the time to neutrophil recovery after autologous peripheral blood stem cell transplantation (PBSCT). We hypothesized that single-dose pegfilgrastim would mimic multiple daily doses of filgrastim, resulting in an equivalent shortening of post-PBSCT neutropenia... CONCLUSION: Pegfilgrastim after PBSCT appears equivalent to multiple daily doses of filgrastim. This approach might be considered in lieu of filgrastim, thus obviating the need for multiple daily injections.
Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. [2010.05]
Nonrandomized trials suggest that pegfilgrastim, a pegylated granulocyte colony-stimulating factor, could be used in lieu of filgrastim after autologus peripheral blood stem cell transplantation...
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. [2010.04]
BACKGROUND: Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency. Pegfilgrastim is indicated to decrease infection as manifested by febrile neutropenia (FN) in patients receiving chemotherapy at > 14-day intervals. This randomized, placebo-controlled phase II study examined pegfilgrastim efficacy and safety in patients with CRC receiving every-2-week chemotherapy... CONCLUSION: Pegfilgrastim was well tolerated in patients with CRC receiving every-2-week chemotherapy and significantly reduced neutropenia and FN compared with placebo, though FN was uncommon in both treatment groups. Results suggest that pegfilgrastim administration is feasible in CRC patients receiving every-2-week chemotherapy.
Clinical Trials Related to Neulasta (Pegfilgrastim)
Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta [Completed]
Efficacy and Safety Study With MYL-1401H and Neulasta [Active, not recruiting]
Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta� [Active, not recruiting]
This is a randomized, double-blind, 2-period parallel study in healthy subjects to assess
immunogenicity and safety of two sequential 6 mg subcutaneous (SC) injections of CHS-1701
compared with two sequential 6 mg SC injections of Neulasta®.
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma [Completed]
In recent years PBPC have replaced bone marrow as the source of hematopoietic stem cells for
autologous transplantation. One of the cited advantages of this procedure is the avoidance
of bone marrow harvest, which frequently requires general anesthesia. Other advantages
include faster neutrophil and platelet engraftment times, faster immune recovery, decrease
in the amount of tumor contamination and technical ability to obtain stem cells from
patients previously considered unharvestable because of marrow fibrosis or because of prior
radiotherapy to the pelvis. Filgrastim has emerged as the preferred cytokine for stem cell
mobilization based on its safety profile and the positive experience in granulocyte donors
however, the number of circulating CD34+ cells does not occur until the third day after
starting filgrastim injections. Pegfilgrastim stimulates the production and maturation of
neutrophil precursors and enhances the functions of mature neutrophils in the same manner as
filgrastim. Data form normal volunteers and in studies of patients with cancer have shown
prolonged serum levels of the cytokine, with "self-regulation" of pegfilgrastim levels as a
function of the neutrophil count. This confers a therapeutic advantage in clinical settings
by allowing a less frequent dosing.
Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim) [Completed]
This is a randomized, double-blind, single-dose, 2-period crossover study in healthy
subjects to assess PK, PD, and safety (including immunogenicity) of a single 6 mg
subcutaneous (SC) injection of CHS-1701 compared with a single 6 mg SC dose of Neulasta®.
Reports of Suspected Neulasta (Pegfilgrastim) Side Effects
Febrile Neutropenia (100),
Neutropenia (83),
Drug Ineffective (68),
Dyspnoea (65),
Pyrexia (63),
Bone Pain (56),
Fatigue (56),
Anaemia (44),
Chest Pain (39),
Nausea (39), more >>
|
|
|
|
Page last updated: 2011-12-09
|
